Prudential Financial
EFTR

Prudential Financial’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Prudential Financial’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-528
Closed -$11K – 2714
2023
Q2 		$11K Buy
+528
New +$8.92K ﹤0.01% 2607

Other funds holding EFTR

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOA
Sea Otter Advisors Miami, Florida $1.78M AUM 2.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prudential Financial's EFTR Position: Q3 2023 in Review

Prudential Financial sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2023, closing a stake of 528 shares — an estimated $11K sold.

Prudential Financial first reported a position in EFTR in Q2 2023 and held it in 1 quarter. The position peaked at $11K in Q2 2023. 29 funds tracked by Wall St. Rank hold EFTR as of Q3 2023.

  • Prudential Financial reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Prudential Financial sold 528 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $11K.
  • Prudential Financial first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Prudential Financial's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $11K in Q2 2023.
  • 29 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Prudential Financial's 13F filing for Q3 2023, filed 13 Nov 2023.